Entrada Advances ELEVATE-44-201 with 12 mg/kg Dose Recommendation, $296M Cash Runway
Entrada has $296 million cash runway into Q3 2027 and advanced ELEVATE-44-201, with an independent committee recommending a 12 mg/kg dose for Cohort 2. The company expects Cohort 1 data in Q2 2026 and Cohort 2 results by year-end, while ELEVATE-45-201 Cohort 1 data are due mid-2026.
1. Financial Results and Cash Position
Entrada reported its fourth quarter and full year 2025 results, ending December 31 with $296 million in cash, cash equivalents and marketable securities, providing runway into the third quarter of 2027.
2. ELEVATE-44-201 Clinical Advancement
An independent Data Monitoring Committee reviewed eight patients in Cohort 1 of the Phase 1/2 ELEVATE-44-201 study and recommended initiation of Cohort 2 at 12 mg/kg. Cohort 1 data (6 mg/kg) are expected in Q2 2026, with Cohort 2 results due by year-end and Cohort 3 (up to 18 mg/kg) to follow.
3. ELEVATE-45-201 and DMD Pipeline Growth
Patient dosing has begun in the global Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 at 5 mg/kg, with Cohort 1 data slated for mid-2026. The company also plans regulatory submissions for ENTR-601-50 and ENTR-601-51 later in 2026, expanding its Duchenne muscular dystrophy franchise.
4. Preclinical Advances and Ocular Candidates
In December 2025, ENTR-801 was nominated to treat Usher syndrome type 2A, and a second oligonucleotide-based ocular candidate is expected to be nominated in the second half of 2026, extending the genetic medicines pipeline beyond neuromuscular disorders.